188 related articles for article (PubMed ID: 3929314)
21. [Cardiovascular effects of (+)- and (-)-tranylcypromine compared to other monoamine oxidase inhibitors in animal studies (author's transl)].
Dénes B; Greeff K; Tawfik H
Arzneimittelforschung; 1982; 32(3):201-7. PubMed ID: 6805481
[TBL] [Abstract][Full Text] [Related]
22. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.
Finberg JP; Youdim MB
Br J Pharmacol; 1985 Jun; 85(2):541-6. PubMed ID: 3928010
[TBL] [Abstract][Full Text] [Related]
23. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.
Fozard JR; Zreika M; Robin M; Palfreyman MG
Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):186-93. PubMed ID: 3937059
[TBL] [Abstract][Full Text] [Related]
24. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
Severina IS
Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
[TBL] [Abstract][Full Text] [Related]
25. The pharmacology of (-)deprenyl.
Knoll J
J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
[TBL] [Abstract][Full Text] [Related]
26. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity].
Severina IS; Klimova GI; Nersisian AA
Biokhimiia; 1981 Nov; 46(11):2043-55. PubMed ID: 6797482
[TBL] [Abstract][Full Text] [Related]
27. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.
Mann JJ; Aarons SF; Wilner PJ; Keilp JG; Sweeney JA; Pearlstein T; Frances AJ; Kocsis JH; Brown RP
Arch Gen Psychiatry; 1989 Jan; 46(1):45-50. PubMed ID: 2491941
[TBL] [Abstract][Full Text] [Related]
28. Biochemical effects of L-deprenyl in atypical depressives.
Liebowitz MR; Karoum F; Quitkin FM; Davies SO; Schwartz D; Levitt M; Linnoila M
Biol Psychiatry; 1985 May; 20(5):558-65. PubMed ID: 3921065
[TBL] [Abstract][Full Text] [Related]
29. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Fuller RW; Hemrick-Luecke SK; Perry KW
J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609
[TBL] [Abstract][Full Text] [Related]
30. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
[TBL] [Abstract][Full Text] [Related]
31. Studies on beta-phenylethylamine deamination by human placental monoamine oxidase.
Oguchi K; Kobayashi S; Uesato T; Kamijo K
Jpn J Pharmacol; 1981 Feb; 31(1):7-14. PubMed ID: 6788990
[TBL] [Abstract][Full Text] [Related]
32. Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl.
Murphy DL; Tamarkin L; Sunderland T; Garrick NA; Cohen RM
Psychiatry Res; 1986 Feb; 17(2):119-27. PubMed ID: 3008207
[TBL] [Abstract][Full Text] [Related]
33. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.
Gal S; Abassi ZA; Youdim MB
Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.
Humphrey SJ; Curry JT; Turman CN; Stryd RP
J Cardiovasc Pharmacol; 2001 May; 37(5):548-63. PubMed ID: 11336106
[TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Goren T; Adar L; Sasson N; Weiss YM
J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
[TBL] [Abstract][Full Text] [Related]
36. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition.
Ansari KS; Yu PH; Kruck TP; Tatton WG
J Neurosci; 1993 Sep; 13(9):4042-53. PubMed ID: 8366359
[TBL] [Abstract][Full Text] [Related]
37. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition.
Cattaneo C; Caccia C; Marzo A; Maj R; Fariello RG
Clin Neuropharmacol; 2003; 26(4):213-7. PubMed ID: 12897643
[TBL] [Abstract][Full Text] [Related]
38. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Riederer P; Youdim MB
J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
[TBL] [Abstract][Full Text] [Related]
39. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl.
Robinson JB
Biochem Pharmacol; 1985 Dec; 34(23):4105-8. PubMed ID: 3933519
[TBL] [Abstract][Full Text] [Related]
40. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
Gleiter CH; Mühlbauer B; Schulz RM; Nilsson E; Antonin KH; Bieck PR
J Neural Transm Gen Sect; 1994; 95(3):241-5. PubMed ID: 7865179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
